Getting smaller, once again.

Quote

anonymous

Guest
The plans for downsizing Oncology and RA are inevitable and were brought up. The maths just doesn't work out anymore for marketing or field. We are bleeding dollars to carry the US sales and marketing teams in the scale that doesn't support the near or mid term outlook. The recent R&D setback and the pandemic make it painfully obvious that we can no longer justify the current scale. In our business, the forecasts dictate every resource allocation.

With the magnitude of the collective impact, the equation has shifted drastically since the beginning of 2020. Now you know why Basel recently signed with Regeneron to make their vaccine. We hate this bloody company with a passion but are desperate to generate cash. In the old days, SSF would have put their people first and Dan often respected that. Not the case anymore. The nice chap appointed there and his current leadership team in SSF are totally clueless, dependent and ruthless by design. They cannot go to pee without calling 41 61 first. By now you should know that they cannot be trusted since they are not even in the loop. Cheers.
 






So Sad. But this was years in the making. No one minded the store and no one cared because they got by and in life looting payroll. It is only now they care because the golden goose is about to get slaughtered. Ba-Bye!
 
























anonymous said:
Oncology will drop to 3-4 reps per ecosystem for oncology except for the top ten ecosystems.
Click to expand...
That’s why I left a few years ago, to many layers calling on the same doctor, we are our worse own enemies. Went to a much smaller company and I love it, freedom, respect, and opportunity to make more money.
 












anonymous said:
Onc reps not needed anymore. Hospitals develop protocols many of which are based on Standard of Care and price.
Click to expand...

In a year or so, the HD's will replace all the TAMs. The HDs will be the only sale personnel and they would call on the networks and payers as GNE will not deal with individual accounts anymore. That's why most of the DMs did not get the HD jobs. This is the ultimate end of the transformation process. This will back fire on them at the end. What GNE did not factor in is the American's demand for choices and options. The younger HCPs will absolutely reject the top down approach. GNE will lose this bet because it's revenue will go down. It will also choke it's R&D and eventually become totally irrelevant.
 






anonymous said:
The plans for downsizing Oncology and RA are inevitable and were brought up. The maths just doesn't work out anymore for marketing or field. We are bleeding dollars to carry the US sales and marketing teams in the scale that doesn't support the near or mid term outlook. The recent R&D setback and the pandemic make it painfully obvious that we can no longer justify the current scale. In our business, the forecasts dictate every resource allocation.


With the magnitude of the collective impact, the equation has shifted drastically since the beginning of 2020. Now you know why Basel recently signed with Regeneron to make their vaccine. We hate this bloody company with a passion but are desperate to generate cash. In the old days, SSF would have put their people first and Dan often respected that. Not the case anymore. The nice chap appointed there and his current leadership team in SSF are totally clueless, dependent and ruthless by design. They cannot go to pee without calling 41 61 first. By now you should know that they cannot be trusted since they are not even in the loop. Cheers.[/QUOTE

As a former Gene’r now with Regeneron, it is unfortunate to see the demise of what was a great, prominent company. Blame it on the Roche acquisition, blame it on the “need” for a dozen oncology reps in a geography, blame it on failed NME’s that didn’t get past trials, whatever. Good luck to all who still think there is a future there, there might be but it won’t be anything like it once was.
Click to expand...
 






anonymous said:
In a year or so, the HD's will replace all the TAMs. The HDs will be the only sale personnel and they would call on the networks and payers as GNE will not deal with individual accounts anymore. That's why most of the DMs did not get the HD jobs. This is the ultimate end of the transformation process. This will back fire on them at the end. What GNE did not factor in is the American's demand for choices and options. The younger HCPs will absolutely reject the top down approach. GNE will lose this bet because it's revenue will go down. It will also choke it's R&D and eventually become totally irrelevant.
Click to expand...


In a year there will be no HD or TAMs in Onc. Everything will be done from the home office via Roche approved contracting. Big $ will be saved.
 






HEDs and HDs are drowning and getting there teeth kicked in by customers who have been waiting for the opportunity after practicing on us for year. Serious contracting by Roche/Genentech isn’t going to happen because of greed. Oncology is history by 2023.
 












GNE used to chase after science and do it right by its people. Now it chases after profits and doesn't blink when it laid off 65% of its field force. Somewhere between the former and latter was greed, arrogance and poor leadership. They underestimated the distant threat and over-estimated its ability to manipulate the market. Most of those leaders got out with their future secured. The causality is always the people on the ground. Some serious lesson to be learnt.
 






anonymous said:
In a year or so, the HD's will replace all the TAMs. The HDs will be the only sale personnel and they would call on the networks and payers as GNE will not deal with individual accounts anymore. That's why most of the DMs did not get the HD jobs. This is the ultimate end of the transformation process. This will back fire on them at the end. What GNE did not factor in is the American's demand for choices and options. The younger HCPs will absolutely reject the top down approach. GNE will lose this bet because it's revenue will go down. It will also choke it's R&D and eventually become totally irrelevant.
Click to expand...
Soon the HDs will have to reinterview for the TAM positions hopefully they will have the right mind set as they did when they stole their reps Tam opportunities. Plus BEMs are the first to go is what I heard what a waste of a group of lazy fake people who lie who are bullies(where's the diversity and inclusion in that?) HR knows.....
 






Top Bottom
Back
Quote